Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
ALMS Stock Chart & Stats
$9.76
-$0.47(-5.84%)
At close: 4:00 PM EST
$9.76
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$2.76 - $12.44
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.20M
Market Cap
$1.03B
Enterprise Value$387.94M
Total Cash (Recent Filing)$377.72M
Total Debt (Recent Filing)$37.80M
Price to Earnings (P/E)―
Beta-2.20
Next Earnings
Mar 25, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding97,208,496
10 Day Avg. Volume875,399
30 Day Avg. Volume1,198,518
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.86
Price to Sales (P/S)0.00
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue17.54
Enterprise Value/Gross Profit18.21
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$20.67Price Target Upside111.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$5.36M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe results reinforce the potential for class-leading TYK2 inhibition to deliver competitive efficacy approaching injectable biologics in an oral compound, portending well for ALMS’ envu.
Financial EfficiencyThe reduction in R&D and SG&A expenses indicates improved financial efficiency, which is expected to fund operations into 2027.
Investor InterestThere is increasing investor interest in the opportunity for envu in lupus, where topline results from ALMS' Phase 2b LUMUS study are expected.
Bears Say
Efficacy RisksRisks include the inability to advance envu into pivotal trials in a timely fashion and failure to show compelling efficacy in key areas.
Phase 3 Program LimitationsTopline details from the Phase 3 LATITUDE program evaluating zaso were somewhat limited.
Trial Advancement RisksRisks include the inability to advance envu into pivotal trials in a timely fashion and failure to secure approval in major markets.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $12.44 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $1.03B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 82 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Nov 13, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.932 by -$0.128.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.95.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 97,208,496 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.932. Following the earnings report the stock price went up 4.545%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (111.78% Upside)
$20.67 (111.78% Upside)
Blogger Sentiment
Bearish
ALMS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.38%
12-Months-Change
Fundamentals
Return on Equity
-66.88%
Trailing 12-Months
Asset Growth
18.29%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$20.67
▲(111.78% Upside)
Technical Analysis
Astria Therapeutics
―
Autolus Therapeutics
―
RAPT Therapeutics
―
ADC Therapeutics
―
AbSci
―
Ownership Overview
Currently, No data available
---